Physician profile
Lori Broderick
NPI 1417152232
$18,123.32
in general payments reported to CMS, 2019-2025
17 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $60.05 · 2021: $225 · 2022: $493 · 2023: $312 · 2024: $15K · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,572 · Travel and Lodging: $7,625 · Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,571.97 |
| Travel and Lodging | $7,625.00 |
| Food and Beverage | $766.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Swedish Orphan Biovitrum Ab | $16,165.00 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $324.75 | 2021-2025 | |
| Grifols USA, LLC | $262.73 | 2021-2024 | Xembify |
| Regeneron Healthcare Solutions, INC. | $247.08 | 2022-2023 | |
| Pfizer INC. | $158.36 | 2019-2021 | |
| Shire North American Group INC | $157.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $128.52 | 2022 | |
| Glaxosmithkline, LLC. | $120.97 | 2023 | Nucala |
| Genzyme Corporation | $114.91 | 2022 | |
| Genentech, INC. | $105.00 | 2022 | |
| Sobi, INC | $101.56 | 2019 | |
| Incyte Corporation | $71.87 | 2023 | |
| Amgen INC. | $64.97 | 2024 | Actimmune |
| Teva Pharmaceuticals USA, INC. | $37.63 | 2020 | |
| Adma Biomanufacturing LLC | $31.97 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hospira, INC. | $16.79 | 2022 | |
| Grifols Shared Services North America, INC. | $13.46 | 2025 | Xembify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Broderick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.